Acquired Immunodeficiency Syndrome (AIDS) (cont.)
Mary D. Nettleman, MD, MS, MACP
Mary D. Nettleman, MD, MS, MACP is the Chair of the Department of Medicine at Michigan State University. She is a graduate of Vanderbilt Medical School, and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Indiana University.
Eric S. Daar, MD
Dr. Daar received his undergraduate degree from UCLA and medical degree from Georgetown University School of Medicine. He completed an internship and residency in internal medicine at Cedars-Sinai Medical Center and his clinical and research fellowship in infectious diseases at Cedars-Sinai Medical Center and UCLA.
In this Article
- Acquired immunodeficiency syndrome (AIDS) facts
- What does AIDS stand for? What causes AIDS?
- What is the history of AIDS?
- What are symptoms and signs of AIDS?
- What are risk factors for developing AIDS?
- How is AIDS diagnosed?
- What is the treatment for HIV/AIDS?
- What is the treatment for HIV during pregnancy?
- What is the treatment for non-HIV-infected people who are exposed to the genital secretions or blood of someone with HIV?
- What are the complications of HIV?
- What is the prognosis for HIV infection?
- Can HIV infection be prevented?
- Is there a vaccine for HIV?
- What research is being done to find a cure for HIV?
- Where can a person find information about clinical trials for HIV and AIDS?
- HIV-AIDS Rxlist FAQs
- Find a local Infectious Disease Specialist in your town
What is the treatment for HIV during pregnancy?
There are two goals of treatment for pregnant women with HIV infection: to treat maternal infection and to reduce the risk of HIV transmission from mother to child. Women can pass HIV to their babies during pregnancy, during delivery, or after delivery by breastfeeding. Without treatment of the mother and without breastfeeding, the risk of transmission to the baby is about 25%. With treatment of the mother before and during birth and with treatment of the baby after birth, the risk decreases to less than 2%. Because of this benefit, it is recommended that all pregnant women be routinely tested for HIV as part of their prenatal care. Once diagnosed, there are several options for treatment, although some antiretroviral medications cannot be used in pregnancy and others have not been studied in pregnancy. For example, the medication efavirenz (Sustiva) is usually avoided in early pregnancy or in women who are likely to become pregnant. Fortunately, there are treatment regimens that have been shown to be well-tolerated by most pregnant women, significantly improving the outcome for mother and child. The same principles of testing for drug resistance and combining antiretrovirals that are used for nonpregnant patients are used for pregnant patients. All pregnant women with HIV should be treated with ART regardless of their CD4 cell count, although the choice of drugs may differ slightly from nonpregnant women. In developed countries, women also are instructed not to breastfeed their children.
Compliance with medications is important to provide the best outcome for mother and child. Even though a physician might highly recommend a medication regimen, the pregnant woman has a choice of whether or not to take the medicines. Studies have shown that compliance is improved when there is good communication between the woman and her doctor, with open discussions about the benefits and side effects of treatment. Compliance also is improved with better social support, including friends and relatives.
Medications are continued throughout pregnancy, labor, and delivery. Some medicines, such as zidovudine (also known as AZT), can be given intravenously during labor, particularly for those women who do not have good viral suppression at the time of delivery. Other medications are continued orally during labor to try to reduce the risk of transmission to the baby during delivery. If the quantity of virus in the mother's blood (viral load) is more than 1,000 copies/mL near the time of delivery, scheduled cesarean delivery is done at 38 weeks gestation to reduce the risk of transmitting the virus during vaginal delivery. Women with HIV who otherwise meet criteria for starting antiretroviral therapy, per local guidelines or the patient's preference, should continue taking ART after delivery for their own health.
If a pregnant woman with HIV infection does not take ART during pregnancy and goes into labor, medications are still given during labor. This reduces the risk of transmission of HIV. After delivery, the infant will be given medication(s) for at least six weeks to reduce the risk of transmission of HIV. If the mother did not take HAART during pregnancy or if the mother has a drug-resistant virus, infants will be treated with multiple medications. Infants are tested periodically in the first six months to ensure they have not acquired the virus.
Get breaking medical news.